SCHEMBL17128293

SCHEMBL17128293

C[C@@H]1CN(c2ccc(Br)cn2)C[C@H](C)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.46
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44
ACACB O00763 1/20 0.42
PDE10A Q9Y233 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
AKR1C3 P42330 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
SMO Q99835 1/20 0.38
GHSR Q92847 2/20 0.37
PANK3 Q9H999 1/20 0.37
OGA O60502 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.36
ACVR1 Q04771 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18149422 0.81 ACVR1 (0.50) HDAC1GRIN2DGRIN3BGRIN1GRIN2A
Hydrochloric Acid SCHEMBL18149424 0.81 ACVR1 (0.50) HDAC1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL25686054 0.81 CNR2 (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13103461 0.81 HDAC1 (0.47) HDAC1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL19001220 0.81 HDAC1 (0.47) HDAC1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL20071406 0.81 CHRNB4 (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL25222660 0.80 CHRNB4 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL17803130 0.80 KMT2A (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3402238 0.80 HDAC1 (0.52) HDAC1GRIN2DGRIN3BGRIN1GRIN2A
Hydrochloric Acid SCHEMBL23607827 0.80 CHRNB4 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
EP-3124482-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-02-01 EP disclosed
WO-2015144001-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS 南京明德新药研发股份有限公司 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH HDAC1 1058/4885GRIN2D 4145/4885GRIN3B 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.